Insights into the Structural Requirements of PKCβII Inhibitors Based on HQSAR and CoMSIA Analyses

Chemical Biology and Drug Design

Volumn 78, Issue 2, 2011, Pages 283-288

  Kumar, Hirdesh ^a   Kumar, Rajendra ^a   Grewal, Baljinder K ^a   Sobhia, M Elizabeth ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

CoMSIA; Fingerprints; Fragments; Holograms; HQSAR; PKC II

Indexed keywords

PROTEIN KINASE C BETA INHIBITOR;

ARTICLE; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; CONTROLLED STUDY; HUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RELIABILITY;

ALGORITHMS; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; MALEIMIDES; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; PROTEIN KINASE C; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 79960348842     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01144.x     Document Type: Article

References (24)

1. Mellor H., Parker P.J. (1998) The extended protein kinase C superfamily. Biochem J;332:281-292.
2. Hug H., Sarre T.F. (1993) Protein kinase C isoenzymes: divergence in signal transduction? Biochem J;291:329-343.
3. Hanks S.K., Hunter T. (1995) Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J;9:576-596.
4. Way K.J., Chou E., King G.L. (2000) Identification of PKC-isoform-specific biological actions using pharmacological approaches. Trends Pharmacol Sci;21:181-187.
5. Inoguchi T., Battan R., Handler E., Sportsman J.R., Heath W., King G.L. (1992) Preferential elevation of protein kinase C isoform ßII and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci;89:11059-11063.
6. Way K.J., Katai N., King G.L. (2001) Protein kinase C and the development of diabetic vascular complications. Diabet Med;18:945-959.
7. Ishii H., Jirousek M.R., Koya D., Takagi C., Xia P., Clermont A., Bursell S.E., Kern T.S., Ballas L.M., Heath W.F. (1996) Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science;272:728-731.
8. Ayo S.H., Radnik R., Garoni J.A., Troyer D.A., Kreisberg J.I. (1991) High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am J Physiol;261:571-577.
9. Grodsky N., Li Y., Bouzida D., Love R., Jensen J., Nodes B., Nonomiya J., Grant S. (2006) Structure of the Catalytic Domain of Human Protein Kinase C [beta] II Complexed with a Bisindolylmaleimide Inhibitor. Biochemistry;45:13970-13981.
10. Newton A.C., Koshland D.E. (1987) Protein kinase C autophosphorylates by an intrapeptide reaction. J Biol Chem;262:10185-10188.
11. Tsutakawa S.E., Medzihradszky K.F., Flint A.J., Burlingame A.L., Koshland D.E. (1995) Determination of in vivo phosphorylation sites in protein kinase C. J Biol Chem;270:26807-26812.
12. Joy S.V., Scates A.C., Bearelly S., Dar M., Taulien C.A., Goebel J.A., Cooney M.J. (2005) Ruboxistaurin, a protein kinase C ß inhibitor, as an emerging treatment for diabetes microvascular complications. Ann Pharmacother;39:1693-1699.
13. Zhang H.C., Derian C.K., McComsey D.F., White K.B., Ye H., Hecker L.R., Li J., Addo M.F., Croll D., Eckardt A.J. (2005) Novel indolylindazolylmaleimides as inhibitors of protein kinase C-[beta]: synthesis, biological activity, and cardiovascular safety. J Med Chem;48:1725-1728.
14. Zhang H.C., White K.B., Ye H., McComsey D.F., Derian C.K., Addo M.F., Andrade-Gordon P., Eckardt A.J., Conway B.R., Westover L. (2003) Macrocyclic bisindolylmaleimides as inhibitors of protein kinase C and glycogen synthase kinase-3. Bioorg Med Chem Lett;13:3049-3053.
15. Zhang H.C., Bonaga L.V.R., Ye H., Derian C.K., Damiano B.P., Maryanoff B.E. (2007) Novel bis (indolyl) maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3. Bioorg Med Chem Lett;17:2863-2868.
16. Zhang H.C., Ye H., Conway B.R., Derian C.K., Addo M.F., Kuo G.H., Hecker L.R., Croll D.R., Li J., Westover L. (2004) 3-(7-Azaindolyl)-4-arylmaleimides as potent, selective inhibitors of glycogen synthase kinase-3. Bioorg Med Chem Lett;14:3245-3250.
17. Powell M.J.D. (1977) Math. Program. 12, 241.
18. Lowis D.R. (1997) HQSAR: a new, highly predictive QSAR technique. Tripos Tech Notes;1:1-17.
19. Seel M., Turner D.B., Willett P. (1999) Effect of parameter variations on the effectiveness of HQSAR analyses. Quant Struct-Act Relat;18:245-252.
20. Klebe G., Abraham U., Mietzner T. (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem;37:4130-4146.
21. Cramer Iii R.D., Bunce J.D., Patterson D.E., Frank I.E. (1988) Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct-Act Relat;7:18-25.
22. Zhang H., Li H., Liu C. (2005) CoMFA, CoMSIA, and molecular hologram QSAR studies of novel neuronal nAChRs ligands-open ring analogues of 3-Pyridyl Ether. J Chem Inf Model;45:440-448.
23. Nair P.C., Sobhia M.E. (2008) Comparative QSTR studies for predicting mutagenicity of nitro compounds. J Mol Graph Model;26:916-934.
24. Chen H., Li Q., Yao X., Fan B.T., Yuan S., Panaye A., Doucet J.P. (2004) CoMFA/CoMSIA/HQSAR and docking study of the binding mode of selective cyclooxygenase (COX-2) inhibitors. QSAR Comb Sci;23:36-55.